ICON Plc’s Acquisition of MedPass International

KPMG advised ICON plc on the deal

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired MedPass International, the leading European medical device CRO, regulatory and reimbursement consultancy, that specialises in medical device development and market access.

This acquisition, concluded in late January, further enhances ICON’s Medical Device and Diagnostic Research Services, through the addition of new regulatory and clinical capabilities in Europe. The integration of MedPass International’s services brings noted expertise in complex class 3 medical devices, interventional cardiology and structural heart devices.

Founded in 1991 and headquartered in Paris, MedPass International is the leading European Medical Device CRO and consultancy. The company has served more than 1,000 medical device companies, from start-ups to multi-nationals, and has contributed to the development of hundreds of innovative devices including a number of breakthrough technologies.

KPMG advised ICON Plc with Xavier Houard and Maud Meotti (Tax DD).

Involved fees earner: Xavier Houard – KPMG; Maud Meotti – KPMG;

Law Firms: KPMG;

Clients: ICON Plc;